Stevanato Group S.p.A. (NYSE:STVN) Shares Purchased by Zions Bancorporation N.A.

Zions Bancorporation N.A. raised its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 29.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 68,017 shares of the company’s stock after buying an additional 15,555 shares during the period. Zions Bancorporation N.A.’s holdings in Stevanato Group were worth $1,482,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Advantage Alpha Capital Partners LP increased its holdings in shares of Stevanato Group by 27.3% in the 4th quarter. Advantage Alpha Capital Partners LP now owns 293,865 shares of the company’s stock valued at $6,403,000 after acquiring an additional 63,041 shares during the last quarter. LPL Financial LLC raised its holdings in Stevanato Group by 24.6% during the fourth quarter. LPL Financial LLC now owns 85,721 shares of the company’s stock worth $1,940,000 after purchasing an additional 16,915 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Stevanato Group during the 4th quarter worth approximately $317,000. Teacher Retirement System of Texas boosted its holdings in shares of Stevanato Group by 56.3% in the 4th quarter. Teacher Retirement System of Texas now owns 1,250,000 shares of the company’s stock valued at $27,238,000 after buying an additional 450,000 shares in the last quarter. Finally, William Blair Investment Management LLC purchased a new position in shares of Stevanato Group in the 4th quarter valued at $1,026,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Wolfe Research started coverage on shares of Stevanato Group in a research report on Friday, December 13th. They issued an “outperform” rating and a $28.00 price target for the company. Morgan Stanley reissued an “equal weight” rating and issued a $23.00 target price (down from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. William Blair restated an “outperform” rating on shares of Stevanato Group in a research note on Friday, March 7th. UBS Group reduced their price objective on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research note on Friday, March 7th. Finally, Bank of America raised their target price on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Stevanato Group has a consensus rating of “Moderate Buy” and a consensus price target of €25.70 ($27.63).

Stevanato Group Stock Down 4.9 %

Stevanato Group stock opened at €21.26 ($22.86) on Wednesday. The stock has a 50 day moving average of €21.03 and a two-hundred day moving average of €20.59. Stevanato Group S.p.A. has a twelve month low of €16.56 ($17.81) and a twelve month high of €33.49 ($36.01). The stock has a market capitalization of $6.44 billion, a price-to-earnings ratio of 45.23, a PEG ratio of 7.18 and a beta of 0.60. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). The firm had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. As a group, research analysts expect that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.